Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas

Vallée, Audrey; Loupp, Anne-Gaëlle Le; Denis, Marc G.

doi:10.1016/j.cca.2013.11.014

Cited by 43 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These limitations of direct sequencing for detecting somatic mutations have led to the development of more sensitive, less expensive, and faster methods. A number of alternative procedures have therefore been developed to detect common cancer mutations, such as HRM [19][20][21], allele-specific amplification [9,[22][23][24], primer extension [25], and pyrosequencing [26]. In most cases, a better sensitivity was obtained using targeted techniques as compared to direct sequencing [27,28] (for a recent review see Ellison et al [29]).…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 98%

EGFR T790M resistance mutation in non small-cell lung carcinoma

Denis

Vallée

Théoleyre

2015

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 98%

EGFR T790M resistance mutation in non small-cell lung carcinoma

Denis

Vallée

Théoleyre

2015

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

“…For example, levels of detection using ddPCR alone can vary from 0.003% [95] to 0.04% [94, 97]. Other PCR-based assays have levels of detection of 0.1% (PNA-clamp) [89] and of 1-2% (in-house allele-specific PCR) [93, 112]. Furthermore, clinically relevant and FDA approved tests such as the Cobas ® EGFR Mutation Test and the Therascreen ® EGFR RGQ PCR test, have reported sensitivities of 0.02% and 0.05-2%, respectively [89, 110, 112].…”

Section: Genetic Analysismentioning

confidence: 99%

Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer

et al. 2016

View full text Add to dashboard Cite

Personalized medicine has emerged as the future of cancer care to ensure that patients receive individualized treatment specific to their needs. In order to provide such care, molecular techniques that enable oncologists to diagnose, treat, and monitor tumors are necessary. In the field of lung cancer, cell free DNA (cfDNA) shows great potential as a less invasive liquid biopsy technique, and next-generation sequencing (NGS) is a promising tool for analysis of tumor mutations. In this review, we outline the evolution of cfDNA and NGS and discuss the progress of using them in a clinical setting for patients with lung cancer. We also present an analysis of the role of cfDNA as a liquid biopsy technique and NGS as an analytical tool in studying EGFR and MET, two frequently mutated genes in lung cancer. Ultimately, we hope that using cfDNA and NGS for cancer diagnosis and treatment will become standard for patients with lung cancer and across the field of oncology.

show abstract

“…8 But this very powerful technique is not yet compatible with routine clinical practice. In our study, DNA extraction and EGFR mutation detection using the approved and efficient 9 Therascreen EGFR RGQ kit (Qiagen, Hilden, Germany) can be performed within 3 hours. We previously described that this procedure allowed us to detect activating EGFR mutations in plasma of advanced non–small-cell lung cancer patients before TKI treatment with a sensitivity of 94.7% and a specificity of 100%.…”

Section: Discussionmentioning

confidence: 99%